Skip to content
20-F

Annual Report (Foreign)

Legend Biotech Corp LEGN

0001801198-26-000008

← back to feed
Filed
Mar 10, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 368.64M sh
Shares Diluted FY 2025 · Dec 31, 2024 365.7M sh
Shares Diluted FY 2025 · Dec 31, 2023 352.17M sh
Shares Outstanding FY 2025 · Dec 31, 2025 369.89M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$100.2M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$144M
Operating Cash Flow restated FY 2025 · Dec 31, 2023 −$393.3M
Cash And Equivalents FY 2025 · Dec 31, 2025 $901.9M
Cash And Equivalents restated FY 2025 · Dec 31, 2024 $286.7M
Cash And Equivalents restated FY 2025 · Dec 31, 2023 $1.28B
Cash And Equivalents restated FY 2025 · Dec 31, 2022 $786M
Stockholders Equity FY 2025 · Dec 31, 2025 $1B
Stockholders Equity restated FY 2025 · Dec 31, 2024 $1.04B
Stockholders Equity restated FY 2025 · Dec 31, 2023 $1.25B
Stockholders Equity restated FY 2025 · Dec 31, 2022 $744.4M
Current Liabilities FY 2025 · Dec 31, 2025 $636.4M
Current Liabilities restated FY 2025 · Dec 31, 2024 $277.7M
Total Liabilities FY 2025 · Dec 31, 2025 $731.6M
Total Liabilities restated FY 2025 · Dec 31, 2024 $629.6M
Current Assets FY 2025 · Dec 31, 2025 $1.25B
Current Assets restated FY 2025 · Dec 31, 2024 $1.28B
Total Assets FY 2025 · Dec 31, 2025 $1.73B
Total Assets restated FY 2025 · Dec 31, 2024 $1.67B
Eps Diluted FY 2025 · Dec 31, 2025 −$0.81
Eps Diluted FY 2025 · Dec 31, 2024 −$0.48
Eps Diluted FY 2025 · Dec 31, 2023 −$1.47
Eps Basic FY 2025 · Dec 31, 2025 −$0.81
Eps Basic FY 2025 · Dec 31, 2024 −$0.48
Eps Basic FY 2025 · Dec 31, 2023 −$1.47
Rd Expense FY 2025 · Dec 31, 2025 $414.7M
Rd Expense restated FY 2025 · Dec 31, 2024 $413.5M
Rd Expense restated FY 2025 · Dec 31, 2023 $382.2M
Net Income FY 2025 · Dec 31, 2025 −$296.8M
Net Income restated FY 2025 · Dec 31, 2024 −$177M
Net Income restated FY 2025 · Dec 31, 2023 −$518.3M
Operating Income FY 2025 · Dec 31, 2025 −$136.5M
Operating Income FY 2025 · Dec 31, 2024 −$309.5M
Operating Income FY 2025 · Dec 31, 2023 −$528.1M
Cost Of Revenue FY 2025 · Dec 31, 2025 $397.1M
Cost Of Revenue restated FY 2025 · Dec 31, 2024 $216.4M
Cost Of Revenue restated FY 2025 · Dec 31, 2023 $144.2M